Norris Medicines Share Price

Norris Medicines Limited was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments. The Company was subsequently converted into Public Limited Company on March 7, 1992. The unit expanded to manufacture Sterile dosage in form of Ampoules Vials. The Company got into the business in the year 1990. Commercial production of the formulation unit commenced in Nov.91. The production unit expanded to manufacture Sterile dosage in form of Ampoules Vials. The project commence in March 1992. Thereafter, the Company came out with a Public Issue aggregating Rs. 5 Crore in December, 1993 to expand its existing capacity for tablets, capsules, etc, besides diversifying into bulk drugs and setting up an injectables unit. The project costing Rs 14.21 Crore was financed through loans and equity, which got completed in 1995.In 2006, the Company launched Diabetic Cardiac products launched Dental product in 2007 launched New Molecule Tolperisone with Paracetamol tablet in 2012 in 2013, it extended Anti malarial range with Artemether Lumefantrine tablet dry syrup. During the year 201314, the Company undertook the upgradation of Sterile Injectable Plant. The Company is one of the leading Indian manufacturers of Injections and Medicinal formulations. The Company is engaged into Health Care Industry and operate 2 plants situated at GIDC, Ankleshwar, Gujarat. Both plants of the Company are WHO GMP approved. At present, it has renovated the Sterile Injectable Plant and with this the plant is now as per international standards.

As of 13 Jun, 2025, NORRIS share price is ₹18. The stock opened at ₹19.4 and had closed at ₹18.9 the previous day. During today’s trading session, NORRIS share price moved between ₹18.01 and ₹19.44, with an average price for the day of ₹18.50. Over the last 52 weeks, the stock has recorded a low of ₹11.30 and a high of ₹27.74. In terms of performance, NORRIS share price has declined by 13.4% over the past six months and has increased by 66.90% over the last year.